Choosing based on reaction history If you consistently experience redness and itching at one particular site, your body may be more reactive to injections in that area
Dulaglutide improves glucocorticoid-induced hyperglycemia in inpatient care and reduces dose and injection frequency of insulin
Not formally approved for weight loss, though weight reduction occurs as a secondary effect
Ideal candidates typically include: Adults with a BMI of 30 or higher (classified as obese) Adults with a BMI of 27 or higher who have at least one weight-related condition, such as type 2 diabetes, hypertension, high cholesterol, PCOS, or obstructive sleep apnea Individuals who have tried diet and exercise consistently but havent achieved meaningful weight loss Patients seeking a non-surgical, medication-based alternative to bariatric procedures People with insulin resistance, prediabetes, or blood sugar management challenges Semaglutide is not recommended for patients who are pregnant, breastfeeding, or planning to conceive, as well as those with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2
doi:10.1007/s10620-023-08122-w